Abstract
Folate coenzymes are involved in biochemical reactions of one-carbon transfer, and deficiency of this vitamin impairs cellular proliferation, migration, and survival in many cell types. Here, the effect of folate restriction on mammary cancer was evaluated using three distinct breast cancer subtypes differing in their aggressiveness and metastatic potential: noninvasive basal-like (E-Wnt), invasive but minimally metastatic claudin-low (M-Wnt), and highly metastatic claudin-low (metM-Wntliver) cell lines, each derived from the same pool of MMTV-Wnt-1 transgenic mouse mammary tumors. NMR-based metabolomics was used to quantitate 41 major metabolites in cells grown in folate-free medium versus standard medium. Each cell line demonstrated metabolic reprogramming when grown in folate-free medium. In E-Wnt, M-Wnt, and metM-Wntliver cells, 12, 29, and 25 metabolites, respectively, were significantly different (P < 0.05 and at least 1.5-fold change). The levels of eight metabolites (aspartate, ATP, creatine, creatine phosphate, formate, serine, taurine and β-alanine) were changed in each folate-restricted cell line. Increased glucose, decreased lactate, and inhibition of glycolysis, cellular proliferation, migration, and invasion occurred in M-Wnt and metM-Wntliver cells (but not E-Wnt cells) grown in folate-free versus standard medium. These effects were accompanied by altered levels of several folate-metabolizing enzymes, indicating that the observed metabolic reprogramming may result from both decreased folate availability and altered folate metabolism. These findings reveal that folate restriction results in metabolic and bioenergetic changes and a less aggressive cancer cell phenotype.
Implications: Metabolic reprogramming driven by folate restriction represents a therapeutic target for reducing the burden of breast cancer. Mol Cancer Res; 15(2); 189–200. ©2016 AACR.
Introduction
Folate coenzymes participate in biochemical reactions of amino acid conversion and nucleotide biosynthesis and serve as acceptors or donors of one-carbon groups (1, 2). Metabolic pathways requiring these coenzymes include the interconversion of serine and glycine, degradation of glycine and histidine, biosynthesis of methionine from homocysteine, and biosynthesis of purine nucleotides and thymidine monophosphate (1, 2). Folate metabolism also plays a key role in the clearance of formate generated via several biochemical reactions in the cell (3, 4) and in mitochondrial translation initiation (2). Furthermore, folate pathways contribute to cellular energy production through oxidation of carbon groups in folate-dependent reactions (5, 6), and folate can serve as an acceptor of formaldehyde during histone demethylation (7). Such diverse roles in metabolic processes make folate indispensable for normal cell function, but it cannot be synthesized by higher animals and must be obtained from dietary sources. Folate deficiency impairs DNA synthesis and repair, changes protein expression patterns, and affects numerous methylation reactions that depend on folate for methionine/SAM biosynthesis; these effects will be eventually translated to deregulation of homeostasis, decreased growth rate, and inhibition of cell division (8–10).
Metabolic reprogramming is one of the hallmarks of cancer (11). Rapidly proliferating cancer cells are especially dependent on an abundant supply of folate to support their metabolic needs for limitless division, including accelerated biosynthesis of nucleotides required for nucleic acids (10). Moreover, folate-dependent serine and glycine synthetic pathways have emerged as crucial for cancer cell proliferation (12, 13). Several studies indicate that increased serine synthesis from glucose in cancer cells is a marker of poor prognosis (14, 15). Serine derived from this pathway donates carbon groups to the de novo purine and thymidine monophosphate biosynthesis, but it can be also used for ATP production; this folate-dependent pathway involves the conversion of serine to glycine and the glycine cleavage system (16). Metabolic flux through this pathway is upregulated at the level of gene expression in a subset of human tumors and correlates with gene signatures defining cellular proliferation (6).
In addition to supporting cellular proliferation, folate pathways are also required to maintain cellular motility, including folate-dependent regulation of tumor cell migration and invasion (10). Positive correlations between the migratory ability of cancer cells and folate supplementation, as well as the inhibitory effects of antifolates on cancer cell migration, have been demonstrated (17, 18). Folate pathways also modulate invasiveness of prostate cancer cells (19) with elevated levels of folic acid promoting both growth and invasiveness of several prostate cancer cell lines (20). Studies from this laboratory have demonstrated that folate regulates motility of A549 human lung cancer cells through an effect on cofilin-dependent actin dynamics (21). Furthermore, the cofilin–actin axis underlies the inhibition of metastasis and increased survival associated with dietary folate restriction in a lung cancer model in SCID mice (22). These results are in apparent conflict with findings of an inhibitory effect of increased folate on invasiveness of HCT116 human colon cancer cells via the activation of sonic hedgehog pathways (23). The same study also reported increased migration of HCT116 cell treated with the antifolate methotrexate (23).
The apparent opposite effect of folate in A549 and HCT116 cells suggests a complex relationship between folate restriction and cancer cell behavior. As these cells were derived from lung and colon tumors, respectively, they are likely to differ in many biological characteristics, including genetic and molecular profiles, metabolic characteristics, stem cell enrichment, invasiveness, and metastatic potential. To better address the biological characteristics contributing to the response to folate restriction, we used a series of cell lines derived from the same tumor that spontaneously arose in MMTV-Wnt-1 transgenic mice. These cell lines, defined as “epithelial (E)-Wnt,” “mesenchymal (M)-Wnt,” and metastatic M-Wnt to the liver (metM-Wntliver), share the same genetic background but vary in terms of molecular profiles, stem cell enrichment, metabolic characteristics, and metastatic potential (24). M-Wnt and E-Wnt cells represent claudin-low and basal-like breast tumors, respectively, according to their gene expression profiles and recapitulated these tumors upon orthotopic transplantation into ovariectomized C57BL/6 mice (24). These cells classify with basal-like triple-negative breast cancers, which represent approximately 20% of all breast cancers and have an especially unfavorable prognosis, high metastatic potential, and are refractory to targeted agents. Here, we report the effect of folate on proliferation and motility of these cell lines and provide data on alterations in metabolic and protein expression profiles induced by folate restriction.
Materials and Methods
Cell culture and reagents
Standard (2.2 μmol/L folic acid) and folate-free RPMI1640 media were obtained from Invitrogen. FBS and dialyzed FBS were purchased from Atlanta Biologicals. Other reagents were from Sigma unless otherwise indicated.
Cell lines
M-Wnt and E-Wnt cells were derived from spontaneous mammary tumors from MMTV-Wnt-1 transgenic mice. These cell lines were tested for species verification, karyotyping, and genomic instability and were authenticated by the Molecular Cytogenetics Core facility at the University of Texas MD Anderson Cancer Center (Houston, TX). Metastatic metM-Wntliver cells were derived from a metastatic liver lesion following orthotopic transplantation of previously authenticated M-Wnt cells (24).
Sample preparation for NMR metabolomics
Cells were grown for 72 hours in 10-cm2 plates in either standard or folate-free medium. Plates at about 80% confluence were placed on ice, media removed, and cells washed three times with ice-cold PBS. After the addition of 1.0 mL acetonitrile chilled to −20°C and 750 μL ice-cold H2O, cells were harvested by scraping and transferred into 15-mL polystyrene tube. This step was repeated using the same volume of acetonitrile/water to ensure that maximal number of cells was collected. After the addition of 1.0 mL chloroform chilled to −20°C and three small glass beads (3 mm diameter), cells were vigorously shaken using a vortex mixer and then centrifuged in swinging bucket rotor (3,000 × g for 20 minutes at 4°C). The top aqueous layer was carefully transferred to 1.5-mL microcentrifuge tubes and lyophilized. The middle layer was collected, dried using a SpeedVac, and the resultant pellet was weighted to assess the total amount of protein. All conditions were collected in triplicate.
NMR spectroscopy
Sodium phosphate buffer solution was prepared by dissolving 1,442.5 mg of NaH2PO4 and 262.5 mg of Na2HPO4 in 100 g of D2O and used without further pH correction (uncorrected pH meter reading 7.59; 100 mmol/L final concentration). Water-soluble metabolite extracts were diluted in 550 μL of buffer containing trimethylsilylpropanoic acid (1.0 mmol/L final concentration). All samples were briefly vortexed and centrifuged for 2 minutes at 14,000 rpm at room temperature, and 500 μL of the resulting supernatant was subsequently transferred to 5-mm tubes (Bruker-Biospin Corporation) for nuclear magnetic resonance (NMR) analysis. All 1H- and 13C-NMR experiments were performed at 298 K on either Bruker Avance II 800 or 600 MHz spectrometers equipped with cryogenically cooled, triple resonance inverse and dual resonance (13C-optimized) DCH cryoprobes with actively shielded Z-gradients, respectively. One-dimensional (1D) 1H spectra of the diluted cell extracts were collected using a Carr–Purcell–Meiboom–Gill pulse sequence. All 1D experiments employed low-power presaturation to suppress residual water. Typically, 1D-1H NMR spectra with a 7-second recycle delay were acquired with a total of 128 transients in addition to 8 dummy scans. A total of 32,768 real data points were collected across a spectral width of 15 ppm (acquisition time: 3.6 seconds). Data were zero-filled to twice the original dataset size, manually phased, and automatically baseline corrected using Topspin 3.1 software (Bruker Biospin Corporation) and the Chenomx NMR suite (version 8.0) program (Chenomx Inc.), respectively. A 0.3 Hz line-broadening apodization was applied prior to spectral analysis.
NMR data analysis
The singlet produced by the known quantity of the TSP methyl groups was used as an internal standard for chemical shift referencing (set to 0 ppm) and for quantification. A targeted metabolite profiling was carried out using the Chenomx NMR suite program (Chenomx Inc.). All spectra were imported into the Chenomx profiling software and concentrations of 41 metabolites were determined. After reference deconvolution was applied based on the 1 mmol/L internal TSP standard line shape, absolute concentrations were determined. Concentrations are expressed as the mean ± SD of the mean. Statistical significance was determined using Student t test without assuming a consistent SD. A P value of <0.05 was considered significant.
Western blot and dot blot assays
Cells were lysed in RIPA buffer containing protease inhibitors cocktail (Sigma). Lysates were normalized by the level of total protein and analyzed by SDS-PAGE followed by immunoblot with corresponding antibodies. 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICART), 10-formyltetrahydrofolate dehydrogenase (ALDH1L1), phosphoribosylglycinamide formyltransferase (GART), glycine N-methyltransferase (GNMT), and cytoplasmic C1-synthase (MTHFD1) were detected using in-house polyclonal antibodies (1:10,000; refs. 25–27). Polyclonal antibodies against thymidylate synthase and cytosolic serine hydroxymethyltransferase (SHMT1; both from Cell Signaling Technology, 1:1,000) and dihydrofolate reductase (DHFR; Abcam, 1:1,000) were used. Polyclonal antibodies against methionine synthase (MTR; 1:1,000) were from Thermo Fisher Scientific. Actin mAb (1:5,000) was from Sigma.
Cell proliferation assay
Cell viability was assessed using an MTT cell proliferation assay (Promega). Cells were plated at a density of 5 × 103 cells/well in a 96-well format, and MTT was added at specified time points. Plates were further processed according to the manufacturer's instructions. Absorbance at 570 nm was read using a Wallace 1420 multilabel counter (PerkinElmer Life Sciences).
Measurements of lactate and glucose
l-lactate levels were measured in cell lysate and medium using a Lactate Colorimetric Assay Kit (Abcam) according to the manufacturer's instructions. Glucose levels in cell lysate were measured using Glucose Colorimetric Assay Kit (Abcam) according to the manufacturer's instructions. In these experiments, cells were grown in standard or folate-free medium for 0 to 72 hours. All experiments were repeated at least twice. Data were normalized to final cell counts.
Transwell invasion assay
Invasion assays were carried out using inserts precoated with extracellular matrix, and the Cell Invasion Assay Kit (Chemicon) according to the manufacturer's protocol. Cells were kept in standard or folate-free medium for 72 hours and then seeded into the upper chamber of a Transwell insert (BD Biosciences) in serum-free medium at a density of 5 × 104 cells/well. Medium containing 10% FBS was placed in the lower chamber as a chemoattractant, and cells were incubated for 24 hours at 37°C in a CO2 incubator. Nonmigrating cells were removed from the upper chamber by scraping; the remaining cells were stained with Diff-Quick dye (Dade Behring, Inc.). Stained cells were counted in 10 random microscopic fields in three independent inserts. Alternatively, stained cells were lysed with 10% acetic acid (100–200 μL/well) and quantified by absorbance at 560 nm. In experiments with replete medium, cells were grown in folate-free medium for 72 hours and then in medium with 2.2 μmol/L folic acid for 72 hours.
Wound healing assay
Cells (3.5 × 104 cells in 70 μL) were seeded in 35-mm μ-Dish culture inserts (ibidi GmbH) and cultured for 24 hours in standard or folate-free medium. Inserts were removed and images of the denuded area were taken at 0, 12, 24, and 48 hours using an inverted microscope (Carl Zeiss, ×5 magnification).
Real-time cell analysis
Experiments were carried out using an xCELLigence RTCA DP instrument (ACEA Biosciences) placed in a humidified incubator at 37°C and 5% CO2 according to the manufacturer's manual. Cell proliferation was monitored using E-plate 16 (ACEA Biosciences). The background impedance reading for each well was set up using cell-free medium (100 μL per well) after preincubation at room temperature for 30 minutes. Cells were seeded in each well in 100 μL cell suspensions across a concentration range of 5 × 103 to 8 × 104 cells/well and allowed to attach for 30 minutes at room temperature. Plates were locked in the instrument, and impedance readings of each well were automatically recorded every 15 minutes for the duration of the experiment. Cell migration experiments were performed using two-chamber CIM-plate 16 (ACEA Biosciences). The background reading was set up in the absence of cells after adding serum-free RPMI1640 medium (50 μL) in the upper chamber and 10% serum-containing RPMI1640 medium (150 μL) in the lower chamber and incubating plates in the instrument for 60 minutes. Cells (4 × 104 in 100 μL) kept on FBS-free medium for 24 hours were seeded in the upper chamber and incubated for 30 minutes at room temperature. Reading was performed as for the proliferation assay.
Metabolic flux analysis
Bioenergetics of cells in the presence or absence of folate was determined using the Seahorse XF96 Analyzer (Agilent Seahorse Technologies). Cells were seeded at a concentration of 1 × 103 or 5 × 103 cells/well and kept in standard or folate-free media for 24 or 48 hours. Prior to measurement, cells were incubated with standard or folate-free RPMI1640 medium supplemented with 2 mmol/L glutamine, 10 mmol/L glucose, and 1 mmol/L sodium pyruvate and incubated for 1 hour at 37°C in a CO2-free atmosphere. Basal oxygen consumption rate (OCR; indicative of mitochondrial respiration) and extracellular acidification rate (ECAR; indicative of lactic acid extrusion following glycolysis) were measured following administration of oligomycin (1 μmol/L), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP; 1 μmol/L), and a combination of antimycin (3 μmol/L) and rotenone (3 μmol/L; XF Cell Mito Stress Test Kit, Agilent Seahorse Technologies). For glycolysis analysis, cells were incubated as above without glucose or sodium pyruvate, and measurements were taken following administration of glucose (10 mmol/L), oligomycin (1 μmol/L), and 2-deoxyglucose (50 mmol/L; XF Glycolysis Stress Test, Agilent Seahorse Technologies). Results were normalized using a bicinchoninic acid protein assay (Thermo Fisher Scientific). All experiments were performed in sextuplicate.
Statistical analysis
Standard errors were calculated using Microsoft Excel or GraphPad Prism. GraphPad Prism was used to calculate P values. Principal component analysis (PCA) was carried out in the programming language R to reduce the dimension of the metabolic profile of each cell line. The first two principal components, that is, PC1 and PC2, are displayed. In the PCA analysis, the cell line data were first mean-centered and subsequently the PCs were computed. The mean-centered data were not further scaled to obtain the z-score before the computation of the PCs.
Results
Levels of major metabolites in Wnt cells
We performed targeted metabolic profiling of E-Wnt, M-Wnt, and metM-Wntliver cells using NMR spectroscopy. This approach allowed us to detect and identify 41 major metabolites, including 15 common amino acids (Table 1). The number of analyzed metabolites in these experiments was limited essentially by the sensitivity of the NMR-based detection, which was about 1 μmol/L, in combination with the regional complexity of the NMR spectrum. PCA was carried out to compare metabolic profiles of three cell lines. This mathematical method allows evaluation of differences between large datasets (levels of 41 compounds for each cell line in our case) upon the reduction of variables to a smaller number (“principal components”) and is commonly used for the analysis of metabolomic data (28, 29). PCA has shown that, based on the overall metabolic signature, samples from the three cell lines are well segregated, indicating that these cell lines are metabolically different (Fig. 1A). Most differences were between the epithelial E-Wnt cell line and the two mesenchymal cell lines (M-Wnt and metM-Wntliver). Levels of eight metabolites (4-aminobutyrate, aspartate, creatine phosphate, glucose, NAD+, proline, taurine, and β-alanine) were 2-fold or more higher, and levels of two metabolites, glycine and putrescine, were approximately 2-fold lower in E-Wnt cells compared with M-Wnt or metM-Wnt cells (Table 1). In addition, levels of ATP, NAD+, and NADP+ were higher in the E-Wnt cells relative to M-Wnt or metM-Wntliver cells (Table 1).
Metabolite . | E-Wnt . | E-Wnt FF . | M-Wnt . | M-Wnt FF . | metM-Wnt . | metM-Wnt FF . |
---|---|---|---|---|---|---|
4-AB | 7.48 ± 0.62 | 8.11 ± 0.94 | 4.67 ± 1.11 | 7.55 ± 2.66 | 4.02 ± 0.59 | 5.93 ± 1.22 |
Acetate | 4.55 ± 1.25 | 5.55 ± 1.36 | 36.55 ± 4.84 | 60.64 ± 1.91 | 5.92 ± 0.76 | 8.4 ± 1.87 |
Alanine | 24.53 ± 8.42 | 30.45 ± 6.61 | 20.52 ± 1.36 | 24.83 ± 7.34 | 16.98 ± 1.89 | 20.7 ± 3.41 |
Asparagine | 15.32 ± 2.03 | 21.16 ± 9.22 | 11.93 ± 2.6 | 21.2 ± 2.53 | 11.23 ± 0.74 | 16.96 ± 2.49 |
Aspartate | 11.9 ± 1.35 | 18.15 ± 2.13 | 2.92 ± 0.86 | 13.2 ± 4.18 | 4.35 ± 0.36 | 12.11 ± 1.47 |
ATP | 47.37 ± 3.83 | 32.23 ± 1.41 | 39.96 ± 2.65 | 13.62 ± 19.9 | 38.51 ± 4.38 | 16.83 ± 2.67 |
cis-Aconitate | 0.03 ± 0 | 0.9 ± 0.62 | 0.04 ± 0 | 1.45 ± 0.27 | 0.04 ± 0 | 0.07 ± 0 |
Creatine | 35.5 ± 5.71 | 6.19 ± 0.84 | 21.19 ± 3.24 | 8.21 ± 14.55 | 10.92 ± 1.48 | 4.38 ± 0.86 |
Creatine-P | 47.41 ± 10.26 | 6.75 ± 0.83 | 1.84 ± 0.52 | 6.18 ± 20.58 | 7.41 ± 1.01 | 3.03 ± 1.3 |
Formate | 2.9 ± 0.33 | 2.18 ± 0.24 | 4.22 ± 0.36 | 6.02 ± 1.55 | 3.93 ± 0.29 | 6.04 ± 0.21 |
Fumarate | 2.4 ± 0.22 | 1.88 ± 0.07 | 1.83 ± 0.5 | 1.58 ± 0.95 | 1.46 ± 0.03 | 0.95 ± 0.18 |
Glucose | 28.89 ± 3.18 | 28.69 ± 15.18 | 12.16 ± 1.18 | 36.07 ± 6.97 | 13.21 ± 4.75 | 29.7 ± 7 |
Glutamate | 72 ± 12.48 | 111.12 ± 47.17 | 55.14 ± 11.14 | 145.42 ± 11.33 | 48.8 ± 5.6 | 103.27 ± 19.43 |
Glutamine | 14.59 ± 2.96 | 20.71 ± 5.17 | 14.96 ± 4.39 | 23.76 ± 3.99 | 12.21 ± 1.29 | 23.44 ± 4.68 |
Glutathione | 28.14 ± 7.17 | 32.16 ± 6.77 | 24.23 ± 5.23 | 37.95 ± 10.08 | 28.19 ± 2.68 | 34.67 ± 6.15 |
Glycine | 49.99 ± 12.84 | 28.88 ± 5.03 | 94.21 ± 6.36 | 114.31 ± 32.52 | 84.49 ± 8.56 | 74.61 ± 11.93 |
GTP | 5.56 ± 0.28 | 3.55 ± 0.54 | 5.16 ± 1.05 | 4.62 ± 2.15 | 4.46 ± 0.5 | 3.23 ± 0.62 |
Histidine | 1.95 ± 0.15 | 2.24 ± 0.44 | 2.16 ± 0.3 | 3.95 ± 0.66 | 1.77 ± 0.29 | 2.9 ± 0.72 |
Isoleucine | 4.16 ± 0.36 | 6.16 ± 1.7 | 5.03 ± 0.29 | 10.75 ± 1.1 | 3.95 ± 0.23 | 6.85 ± 1.09 |
Lactate | 163.69 ± 20.9 | 127.06 ± 25.22 | 210.3 ± 8.05 | 93.97 ± 67.94 | 174.42 ± 13.5 | 58.53 ± 6.56 |
Leucine | 5.17 ± 0.44 | 6.32 ± 1.52 | 5.77 ± 0.45 | 12.13 ± 1.64 | 4.86 ± 0.39 | 7.9 ± 1.12 |
Mannose | 5.83 ± 1.2 | 4.59 ± 0.37 | 5.2 ± 0.98 | 5.83 ± 2.25 | 3.92 ± 0.06 | 3.22 ± 0.12 |
Methionine | 2.12 ± 0.7 | 3.03 ± 0.42 | 2.1 ± 0.45 | 4.7 ± 0.82 | 2.22 ± 0.16 | 2.69 ± 0.46 |
Myo-inositol | 17.26 ± 1.04 | 21.49 ± 6.32 | 13.19 ± 0.26 | 49.54 ± 4.5 | 10.56 ± 0.95 | 28.12 ± 2.78 |
NAD+ | 8.25 ± 0.79 | 7.06 ± 1.14 | 5.55 ± 0.84 | 6.41 ± 2.9 | 4.88 ± 0.26 | 5.56 ± 1.09 |
NADH | 1.16 ± 0.22 | 0.72 ± 0.18 | 0.84 ± 0.35 | 1 ± 0.4 | 0.86 ± 0.22 | 0.62 ± 0.15 |
NADP+ | 1.18 ± 0 | 0.85 ± 0.15 | 0.74 ± 0.03 | 0.81 ± 0.41 | 0.61 ± 0.12 | 0.77 ± 0.11 |
Phenylalanine | 1.31 ± 0.1 | 1.39 ± 0.34 | 2.31 ± 0.29 | 4.07 ± 0.47 | 1.38 ± 0.21 | 2.34 ± 0.87 |
Proline | 19.14 ± 2 | 22.5 ± 6.73 | 11.76 ± 1.24 | 28.61 ± 5.15 | 10.88 ± 0.62 | 18.5 ± 2.17 |
Putrescine | 6.7 ± 1.06 | 8.56 ± 1.49 | 14.58 ± 0.77 | 14.35 ± 3.53 | 10.09 ± 1.02 | 11.34 ± 1.89 |
Serine | 11.44 ± 1.81 | 22.81 ± 6.29 | 12.51 ± 2.92 | 35.24 ± 3.04 | 13.53 ± 1.07 | 29.59 ± 4.48 |
G3PC | 4.43 ± 0.54 | 2.88 ± 0.56 | 3.71 ± 0.51 | 7.2 ± 1.59 | 2.9 ± 0.34 | 2.37 ± 0.35 |
Succinate | 3.75 ± 0.49 | 3.29 ± 0.36 | 2.95 ± 0.34 | 3.09 ± 1.43 | 2.88 ± 0.1 | 2.41 ± 0.5 |
Taurine | 60.69 ± 5.01 | 13.06 ± 1.06 | 37.88 ± 12.13 | 10.88 ± 24.4 | 27.16 ± 2.37 | 5.32 ± 0.46 |
Tryptophan | 1.16 ± 0.24 | 0.94 ± 0.41 | 1.48 ± 0.2 | 2.08 ± 0.37 | 0.32 ± 0.2 | 0.9 ± 0.09 |
Tyrosine | 1.86 ± 0.17 | 2.36 ± 0.5 | 2.25 ± 0.18 | 4.44 ± 0.65 | 1.91 ± 0.28 | 3.08 ± 0.57 |
UDP-Glc | 5.05 ± 0.2 | 4.83 ± 1.49 | 4.61 ± 0.38 | 7.31 ± 1.46 | 3.7 ± 0.28 | 5.31 ± 0.61 |
UDP-Glcr | 2.65 ± 0.42 | 2.19 ± 0.34 | 3.14 ± 0.21 | 5.62 ± 1.44 | 3.81 ± 0.21 | 4.7 ± 0.07 |
UDP-NAG | 2.77 ± 0.36 | 1.98 ± 0.69 | 1.26 ± 0.56 | 0.95 ± 0.91 | 2.47 ± 0.18 | 2.39 ± 0.58 |
Valine | 1.8 ± 0.31 | 2.19 ± 0.3 | 2.26 ± 0.32 | 4.5 ± 0.72 | 1.87 ± 0.09 | 3.38 ± 0.59 |
β-Alanine | 19.15 ± 4.39 | 10.77 ± 0.23 | 6.83 ± 1.71 | 18.4 ± 8.3 | 3.21 ± 0.2 | 2.23 ± 0.3 |
Metabolite . | E-Wnt . | E-Wnt FF . | M-Wnt . | M-Wnt FF . | metM-Wnt . | metM-Wnt FF . |
---|---|---|---|---|---|---|
4-AB | 7.48 ± 0.62 | 8.11 ± 0.94 | 4.67 ± 1.11 | 7.55 ± 2.66 | 4.02 ± 0.59 | 5.93 ± 1.22 |
Acetate | 4.55 ± 1.25 | 5.55 ± 1.36 | 36.55 ± 4.84 | 60.64 ± 1.91 | 5.92 ± 0.76 | 8.4 ± 1.87 |
Alanine | 24.53 ± 8.42 | 30.45 ± 6.61 | 20.52 ± 1.36 | 24.83 ± 7.34 | 16.98 ± 1.89 | 20.7 ± 3.41 |
Asparagine | 15.32 ± 2.03 | 21.16 ± 9.22 | 11.93 ± 2.6 | 21.2 ± 2.53 | 11.23 ± 0.74 | 16.96 ± 2.49 |
Aspartate | 11.9 ± 1.35 | 18.15 ± 2.13 | 2.92 ± 0.86 | 13.2 ± 4.18 | 4.35 ± 0.36 | 12.11 ± 1.47 |
ATP | 47.37 ± 3.83 | 32.23 ± 1.41 | 39.96 ± 2.65 | 13.62 ± 19.9 | 38.51 ± 4.38 | 16.83 ± 2.67 |
cis-Aconitate | 0.03 ± 0 | 0.9 ± 0.62 | 0.04 ± 0 | 1.45 ± 0.27 | 0.04 ± 0 | 0.07 ± 0 |
Creatine | 35.5 ± 5.71 | 6.19 ± 0.84 | 21.19 ± 3.24 | 8.21 ± 14.55 | 10.92 ± 1.48 | 4.38 ± 0.86 |
Creatine-P | 47.41 ± 10.26 | 6.75 ± 0.83 | 1.84 ± 0.52 | 6.18 ± 20.58 | 7.41 ± 1.01 | 3.03 ± 1.3 |
Formate | 2.9 ± 0.33 | 2.18 ± 0.24 | 4.22 ± 0.36 | 6.02 ± 1.55 | 3.93 ± 0.29 | 6.04 ± 0.21 |
Fumarate | 2.4 ± 0.22 | 1.88 ± 0.07 | 1.83 ± 0.5 | 1.58 ± 0.95 | 1.46 ± 0.03 | 0.95 ± 0.18 |
Glucose | 28.89 ± 3.18 | 28.69 ± 15.18 | 12.16 ± 1.18 | 36.07 ± 6.97 | 13.21 ± 4.75 | 29.7 ± 7 |
Glutamate | 72 ± 12.48 | 111.12 ± 47.17 | 55.14 ± 11.14 | 145.42 ± 11.33 | 48.8 ± 5.6 | 103.27 ± 19.43 |
Glutamine | 14.59 ± 2.96 | 20.71 ± 5.17 | 14.96 ± 4.39 | 23.76 ± 3.99 | 12.21 ± 1.29 | 23.44 ± 4.68 |
Glutathione | 28.14 ± 7.17 | 32.16 ± 6.77 | 24.23 ± 5.23 | 37.95 ± 10.08 | 28.19 ± 2.68 | 34.67 ± 6.15 |
Glycine | 49.99 ± 12.84 | 28.88 ± 5.03 | 94.21 ± 6.36 | 114.31 ± 32.52 | 84.49 ± 8.56 | 74.61 ± 11.93 |
GTP | 5.56 ± 0.28 | 3.55 ± 0.54 | 5.16 ± 1.05 | 4.62 ± 2.15 | 4.46 ± 0.5 | 3.23 ± 0.62 |
Histidine | 1.95 ± 0.15 | 2.24 ± 0.44 | 2.16 ± 0.3 | 3.95 ± 0.66 | 1.77 ± 0.29 | 2.9 ± 0.72 |
Isoleucine | 4.16 ± 0.36 | 6.16 ± 1.7 | 5.03 ± 0.29 | 10.75 ± 1.1 | 3.95 ± 0.23 | 6.85 ± 1.09 |
Lactate | 163.69 ± 20.9 | 127.06 ± 25.22 | 210.3 ± 8.05 | 93.97 ± 67.94 | 174.42 ± 13.5 | 58.53 ± 6.56 |
Leucine | 5.17 ± 0.44 | 6.32 ± 1.52 | 5.77 ± 0.45 | 12.13 ± 1.64 | 4.86 ± 0.39 | 7.9 ± 1.12 |
Mannose | 5.83 ± 1.2 | 4.59 ± 0.37 | 5.2 ± 0.98 | 5.83 ± 2.25 | 3.92 ± 0.06 | 3.22 ± 0.12 |
Methionine | 2.12 ± 0.7 | 3.03 ± 0.42 | 2.1 ± 0.45 | 4.7 ± 0.82 | 2.22 ± 0.16 | 2.69 ± 0.46 |
Myo-inositol | 17.26 ± 1.04 | 21.49 ± 6.32 | 13.19 ± 0.26 | 49.54 ± 4.5 | 10.56 ± 0.95 | 28.12 ± 2.78 |
NAD+ | 8.25 ± 0.79 | 7.06 ± 1.14 | 5.55 ± 0.84 | 6.41 ± 2.9 | 4.88 ± 0.26 | 5.56 ± 1.09 |
NADH | 1.16 ± 0.22 | 0.72 ± 0.18 | 0.84 ± 0.35 | 1 ± 0.4 | 0.86 ± 0.22 | 0.62 ± 0.15 |
NADP+ | 1.18 ± 0 | 0.85 ± 0.15 | 0.74 ± 0.03 | 0.81 ± 0.41 | 0.61 ± 0.12 | 0.77 ± 0.11 |
Phenylalanine | 1.31 ± 0.1 | 1.39 ± 0.34 | 2.31 ± 0.29 | 4.07 ± 0.47 | 1.38 ± 0.21 | 2.34 ± 0.87 |
Proline | 19.14 ± 2 | 22.5 ± 6.73 | 11.76 ± 1.24 | 28.61 ± 5.15 | 10.88 ± 0.62 | 18.5 ± 2.17 |
Putrescine | 6.7 ± 1.06 | 8.56 ± 1.49 | 14.58 ± 0.77 | 14.35 ± 3.53 | 10.09 ± 1.02 | 11.34 ± 1.89 |
Serine | 11.44 ± 1.81 | 22.81 ± 6.29 | 12.51 ± 2.92 | 35.24 ± 3.04 | 13.53 ± 1.07 | 29.59 ± 4.48 |
G3PC | 4.43 ± 0.54 | 2.88 ± 0.56 | 3.71 ± 0.51 | 7.2 ± 1.59 | 2.9 ± 0.34 | 2.37 ± 0.35 |
Succinate | 3.75 ± 0.49 | 3.29 ± 0.36 | 2.95 ± 0.34 | 3.09 ± 1.43 | 2.88 ± 0.1 | 2.41 ± 0.5 |
Taurine | 60.69 ± 5.01 | 13.06 ± 1.06 | 37.88 ± 12.13 | 10.88 ± 24.4 | 27.16 ± 2.37 | 5.32 ± 0.46 |
Tryptophan | 1.16 ± 0.24 | 0.94 ± 0.41 | 1.48 ± 0.2 | 2.08 ± 0.37 | 0.32 ± 0.2 | 0.9 ± 0.09 |
Tyrosine | 1.86 ± 0.17 | 2.36 ± 0.5 | 2.25 ± 0.18 | 4.44 ± 0.65 | 1.91 ± 0.28 | 3.08 ± 0.57 |
UDP-Glc | 5.05 ± 0.2 | 4.83 ± 1.49 | 4.61 ± 0.38 | 7.31 ± 1.46 | 3.7 ± 0.28 | 5.31 ± 0.61 |
UDP-Glcr | 2.65 ± 0.42 | 2.19 ± 0.34 | 3.14 ± 0.21 | 5.62 ± 1.44 | 3.81 ± 0.21 | 4.7 ± 0.07 |
UDP-NAG | 2.77 ± 0.36 | 1.98 ± 0.69 | 1.26 ± 0.56 | 0.95 ± 0.91 | 2.47 ± 0.18 | 2.39 ± 0.58 |
Valine | 1.8 ± 0.31 | 2.19 ± 0.3 | 2.26 ± 0.32 | 4.5 ± 0.72 | 1.87 ± 0.09 | 3.38 ± 0.59 |
β-Alanine | 19.15 ± 4.39 | 10.77 ± 0.23 | 6.83 ± 1.71 | 18.4 ± 8.3 | 3.21 ± 0.2 | 2.23 ± 0.3 |
NOTE: Levels were normalized per mg protein. Averages of three measurements are shown.
Abbreviations: 4-AB, 4-aminobutirate; creatine-P, creatine phosphate; G3PC, sn-glycero-3-phosphocholine; Glc, glucose; Glcr, glucuronate; NAG, N-acetylglucosamine.
Alterations in major metabolites in response to folate restriction
Significant changes in response to folate restriction were observed in each of the cell lines with generally stronger effects on mesenchymal cells than epithelial cells (Table 1). PCA performed for metabolic profiles of cells growing in standard (control) versus folate-free medium demonstrated clear and strong treatment-dependent segregation in each case (Fig. 1B), which we interpreted as metabolic reprogramming. Statistically significant changes (P < 0.05) in levels of 12 metabolites occurred in E-Wnt cells as compared with 29 and 25 metabolites, respectively, in M-Wnt and metM-Wntliver cells (Table 1). Eight metabolites (aspartate, ATP, creatine, creatine phosphate, formate, serine, taurine, and β-alanine) were changed in all cell lines, with five of them (aspartate, ATP, creatine, serine, and taurine) altered in the same direction in each cell line (Table 1). Between M-Wnt and metM-Wntliver cells, 22 metabolites were commonly changed with 20 of them altered in a similar way (up or down) and two metabolites (creatine phosphate and β-alanine) changed differently (Table 1; Fig. 1C).
Statistically significant elevations in serine and myo-inositol, and reductions in creatine and taurine, were detected in all cell lines after folate restriction (Table 1; Fig. 1C). Taurine and serine were changed to about the same extent in all cells; changes in myo-inositol were less prominent in E-Wnt cells, while levels of creatine decreased more in E-Wnt cells than in M-Wnt or metM-Wntliver cells (Table 1; Fig. 1C). Most amino acids with the exception of glycine were elevated in cells grown on folate-free media (Table 1; Fig. 1C). This trend had a higher magnitude in two mesenchymal cell lines (Fig. 1C). In mesenchymal cells, strong accumulation of glucose was observed with concomitant drop in lactate upon folate restriction, whereas levels of glucose were not changed in epithelial cells with only marginal decrease of lactate levels (Table 1; Fig. 1C). Overall, clustering of samples after PCA has shown that following folate restriction, both mesenchymal cell lines were very different metabolically from epithelial E-Wnt cells but were indistinguishable from each other (Fig. 1A).
Changes in folate enzymes
Using Western blot assays, we evaluated changes in levels of several key folate enzymes in response to folate starvation. No noticeable increase in the levels of any of tested folate enzyme was observed, while cell type-specific downregulation of several targets was apparent after folate withdrawal (Fig. 2A). Levels of several enzymes were not changed in Wnt cells, including TYMS, MTR, and the folate-dependent enzyme in the de novo purine biosynthesis, AICART (Fig. 2A). Another folate-dependent enzyme in the de novo purine pathway, GART, was noticeably downregulated in each cell line (Fig. 2A). Dihydrofolate reductase, the key enzyme to convert dietary folic acid to tetrahydrofolate, was downregulated in mesenchymal-type cells (M-Wnt and metM-Wntliver) but not epithelial E-Wnt (Fig. 2A). Conversely, strong decreases in levels of MTHFD1 and SHMT1 were observed in E-Wnt cells with no changes for the latter protein and marginal changes in the former protein in M-Wnt and metM-Wntliver cells (Fig. 2A). Two folate enzymes, ALDH1L1 and GNMT, were not detected in any of the three cell lines (Fig. 2A), which is in agreement with the reported ubiquitous loss of these proteins in malignant tumors (25, 27). Western blot data were confirmed by dot blot assays (Supplementary Fig. S1), which allows a more robust assessment of proteins levels using triplicates of multiple sample dilutions to both increase accuracy and ensure that observed differences were not the result of sample variations. Reactions catalyzed by corresponding enzymes are depicted in Fig. 2B.
Metabolic flux analysis
Alterations in intracellular glucose and lactate levels in response to folate restriction were assessed using colorimetric assays and indicated the impairment of glycolysis. In cells maintained in a standard culture medium, both intracellular and extracellular levels of lactate increased in time-dependent manner (Fig. 3). In contrast, both intracellular and extracellular lactate levels were decreased if cells were cultured in folate-free media (Fig. 3). Likewise, compared with cells grown in control (standard) media, glucose levels were increased in M-Wnt and metM-Wntliver (but not E-Wnt) cells grown in folate-free medium (Fig. 3). These results were consistent with NMR metabolomic profiling experiments (Table 1; Fig. 1C). We further used a Seahorse metabolic analyzer to examine metabolic flux in cells grown in standard or folate-free medium. We observed that folate depletion resulted in significantly decreased OCR in E-Wnt, M-Wnt, and metM-Wntliver cell lines (Fig. 4). Inhibition of ATP synthase with oligomycin (mitochondrial stress test) and incubation with mitochondrial uncoupler FCCP demonstrated that folate-depleted cells display reduced ATP production and reduced maximal mitochondrial respiration, as well as reduced respiratory capacity (the difference between maximal and basal OCR; Fig. 4). Folate restriction also caused a significant reduction in glycolysis, as measured by ECAR following stimulation with glucose (Fig. 4). In addition, all cell lines displayed reduced maximal glycolysis rate following incubation with oligomycin, and decreased glycolytic reserve (the difference between maximal and glucose stimulated ECAR; Fig. 4). Overall, our data indicated the impairment of both mitochondrial respiration and glycolysis upon folate withdrawal from culture medium. Of note, the effect of folate restriction was stronger in M-Wnt and metM-Wntliver cells than in E-Wnt cells (Fig. 4).
Proliferation and migration of Wnt cells
To investigate how the observed metabolic reprogramming following folate restriction influences cellular behavior, we evaluated the effect of folate withdrawal on cellular proliferation, invasion, and migration. All three tested cell lines, E-Wnt, M-Wnt, and metM-Wntliver, were sensitive to the loss of folate: proliferation was essentially arrested by 48 hours of folic acid withdrawal from the media (Fig. 5A). Significant cell death was observed if cells were cultured without folate for more than 72 hours (data not shown). As assessed by the transwell assay, folate restriction (72 hours in folate-free medium) strongly inhibited cell invasion with a more profound effect observed in M-Wnt cells than either E-Wnt or metM-Wntliver cells (Fig. 5B and C). This inhibitory effect was reversible upon repletion of cell culture medium with folic acid (Fig. 5B and C). Wound healing scratch assays further indicated that the migration of Wnt cells was strongly inhibited in the absence of folate (Supplementary Fig. S2). We have also measured cellular migration using impedance-based ACEA technology (30). The setup in this approach corresponds to the conventional transwell assay but allows the constant monitoring of migration in real time and minimizes the input of cell proliferation. The real-time monitoring of cellular migration confirmed that folate restriction more strongly affected migration of cells with mesenchymal (M-Wnt and metM-Wntliver) relative to epithelial (E-Wnt) phenotype (Fig. 5D–F). Similar to invasion, the effect of folate restriction on migration was reversible: Cells restored their proliferation and migration capacity after folate in medium was replete (data not shown).
Discussion
Folate is involved in several major metabolic processes (Fig. 2B), and modulation of folate levels has a pleiotropic effect on the cell, directly or indirectly influencing levels of numerous metabolites (pathways connecting folate metabolism to metabolites altered in our study are depicted in Fig. 6). Targeting folate metabolism using antifolates, such as methotrexate and aminopterin, was one of the earliest cancer chemotherapeutic approaches (31). However, antifolates, and more recently specific inhibitors aimed at counteracting upregulation of key biosynthetic/salvage enzymes involved in folate metabolism, are typically quite toxic and prone to inducing tumor cell resistance (31). Folate-restricted diets have been suggested as a possible alternative to pharmacologic antifolate agents, but the limited studies to date regarding breast cancer have shown both enhancing and inhibitory effects of low-folate diets and suggest factors such as tumor stage and molecular subtype can influence the effect of folate restriction on breast cancer. To begin to deconvolute the complex relationship between folate restriction and breast cancer, we assessed folate restriction effects on mammary cancer cell lines (derived from MMTV-Wnt-1 transgenic mouse mammary tumors) with differential metastatic potential and molecular characteristics. Cells representing basal-like (epithelial type E-Wnt cell line) and claudin-low (mesenchymal M-Wnt and metM-Wntliver cell lines) breast tumors were analyzed. We found that folate-free medium, compared with standard medium containing 2.2 μmol/L folic acid, induced changes in several metabolites (serine, glycine, histidine, formate, and taurine) and decreased some key folate enzymes involved in the metabolism of serine, glycine, and formate and supporting the flux of one-carbon groups to the intracellular folate pool. Significant changes in levels of glucose and several metabolites derived from glucose were observed in mesenchymal (M-Wnt and metM-Wntliver) cells but not in epithelial E-Wnt cells. Folate restriction also strongly inhibited glycolysis in M-Wnt and metM-Wntliver cells in association with inhibition of cellular proliferation, migration, and invasion. Overall, our findings indicated that folate restriction can initiate cell type-specific metabolic reprogramming of breast cancer cells toward a less aggressive phenotype.
On the basis of metabolic pathways of folate (1, 2), the immediate downstream effects of altered levels of folate should be on serine, glycine, histidine, methionine, homocysteine, formate, and nucleotides (Fig. 2B). Interestingly, we have observed that overall levels of amino acids in folate-starved cells are increased, although this increase is marginal in E-Wnt cells (Fig. 1C). We have interpreted this effect as an indication of decreased protein synthesis, consistent with the antiproliferative effect of folate restriction observed in the three studied cell lines. Although levels of most amino acids were elevated upon folate restriction, levels of glycine were only marginally elevated in M-Wnt cells but decreased in two other cell lines. This finding is in agreement with the deficiency of folate coenzymes, which would prevent the generation of glycine from serine. It should be noted that the consumption of extracellular glycine is not sufficient to support metabolic needs of cancer cells (32). Furthermore, strong elevation of serine, as well as the elevation of histidine and formate (Table 1; Fig. 1C), fit the signature of folate deficiency. The drop in ATP observed in folate-starved cells conforms with recent findings that folate pathways contribute to cellular energy production (5, 6). This ATP reduction was less profound in E-Wnt cells, possibly due to input of activated phosphate groups from creatine phosphate. Indeed, a significant decrease in creatine phosphate upon folate withdrawal was measured in E-Wnt cells but not M-Wnt or metM-Wntliver cells (Table 1). Although the replenishment of ATP by creatine phosphate is a well-known phenomenon, the capacity of this process in M-Wnt and metM-Wntliver cells might be insufficient due to low levels of creatine phosphate in these cells.
Levels of several metabolites not directly relevant to folate pathways were significantly changed upon folate restriction. Of particular interest was the drop in lactate with simultaneous elevation of glucose, a phenomenon observed only in mesenchymal M-Wnt and metM-Wntliver cells but not E-Wnt cells. In many tumor types, high lactate production and concentration have been associated with increased migratory ability and invasiveness of cancer cells, more aggressive cancer stages, and metastasis (33, 34). Although changes in metabolites not associated directly with folate metabolism could be a consequence of inhibited proliferation, at least in the case of lactate, our results suggest otherwise. Thus, strong differences in levels of lactate between cells grown in standard versus folate-free medium were recorded at time points when proliferation was not yet arrested (compare Figs. 3 and 5A).
One advantage of a high glycolytic rate in cancer cells is the acidification of the tumor microenvironment by lactate extrusion, which is associated with higher proliferation, migration and invasion, angiogenesis, and increased cell survival (35). For example, the decrease of lactate production by knocking down lactate dehydrogenase inhibits migration and invasion of 4T1 breast cancer cells (36). Similar effects were demonstrated in several cancer cell lines by targeting lactate transporters (37, 38). Lactate may also serve as a signaling molecule in breast cancer regulating nutrient uptake and potentially cell viability, proliferation, and migratory capacity (39). In addition, through the conversion to pyruvate, lactate can be used for energy generation, particularly in breast tumors (33, 40). Thus, within the same tumor, lactate produced by glycolytic tumor cells can be consumed by oxidative tumor cells for energy generation (41). In our study, the drop in lactate in folate-deficient cells was not associated with increased lactate excretion, as the extracellular concentrations of this metabolite were also significantly decreased. Although such a drop could be associated with enhanced lactate utilization for the energy production, the accumulation of glucose in folate-deficient cells was in agreement with the decreased lactate generation. Likewise, metabolic profiling using Seahorse technology indicated reduced glycolytic capacity in folate-starved cells with stronger effect on mesenchymal (M-Wnt and metM-Wntliver) cells.
In recent years, numerous studies have attempted to use metabolomic data to define a signature for tumorigenic potential of different malignancies, including breast tumors (42). Lactate, taurine, glucose, and myo-inositol have been linked with tumor aggressiveness, although precise associations between their levels and disease need further clarification (34, 42, 43). Interestingly, changes of these four metabolites in folate deficient versus folate supplemented M-Wnt and metM-Wntliver cells (Fig. 1C) mirror the pattern of their alterations in colorectal cancer, where glucose and myo-inositol are decreased, whereas lactate and taurine are increased compared with normal tissues (34). Specifically to myo-inositol, it has been also reported that this metabolite was significantly increased in breast cancer survivors who underwent chemotherapy (44), and in healthy control subjects compared with men with prostate cancer (45). These findings suggest that the drop in myo-inositol levels is a common trend in malignancies. Accordingly, significantly increased levels of myo-inositol in folate-restricted cells imply a shift toward less aggressive phenotype, which is in agreement with the loss of migratory and invasive ability in these cells. Although it is unclear how folate restriction results in the elevation of myo-inositol, this elevation was accompanied by an elevation of glucose, the substrate for myo-inositol biosynthesis (46). Levels of taurine, which in our study significantly decreased with folate restriction, have been used in several studies as a tumor marker (43, 47–49). Relevant to our study, levels of taurine increased in breast cancer biopsies (50) yet decreased in MCF-7 breast cancer cells treated with curcumin, a compound with known antiproliferative activity (51). Thus, decreased taurine levels in response to folate restriction may be indicative of an overall antiproliferative effect. Interestingly, while creatine levels were decreased in all cell lines, a much greater decrease occurred in E-Wnt cells. To the best of our knowledge, creatine levels have not previously been investigated with regard to folate status. Creatine synthesis, however, might have connections to folate metabolism: Glycine and SAM, required for this pathway, could originate from folate metabolism (Fig. 6).
The observed changes in the pattern of major metabolites in response to folate restriction were associated with the strong inhibition of cellular proliferation, migration, and invasion of mammary cancer cells. The immediate effect of folate restriction on cellular processes most likely is associated with the direct input on specific folate-dependent biochemical reactions. Thus, recent studies underscore a link between folate-dependent serine and glycine metabolism and cellular proliferation, migration, and overall aggressiveness of tumors (6, 32, 52). Further downstream effects could be mediated by alterations in the protein expression profile, a phenomenon reported previously for folate deficiency (53). In our study, folate restriction led to the decrease of levels of some folate enzymes with a more strong effect observed for SHMT1 and MTHFD1 in E-Wnt cells. Of note, MTHFD1 has previously been linked to melanoma metastasis (54). Although the effect of folate withdrawal can perhaps be additionally mediated by alterations of folate enzymes, we suggest that the primary effect on cellular metabolite is due to the direct input on folate-dependent reactions. Overall, we conclude that restriction of folate in mammary cancer cells reprograms cellular metabolism toward a less proliferative or migratory phenotype, with a more profound effect exerted in cells with a mesenchymal, relative to an epithelial, phenotype. Folate restriction–related metabolic reprogramming may therefore represent a therapeutic target for reducing the burden of breast tumors that have undergone EMT, such as claudin-low breast cancers.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Authors' Contributions
Conception and design: M. Hennig, S.D. Hursting, S.A. Krupenko
Development of methodology: M. Hennig, S.A. Krupenko
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. O'Flanagan, M. Hennig
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Z. Ashkavand, C. O'Flanagan, M. Hennig, X. Du, S.D. Hursting, S.A. Krupenko
Writing, review, and/or revision of the manuscript: C. O'Flanagan, M. Hennig, X. Du, S.D. Hursting, S.A. Krupenko
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.D. Hursting
Study supervision: S.D. Hursting, S.A. Krupenko
Other (performed all cell culture experiments): Z. Ashkavand
Acknowledgments
The authors would like to thank Dr. Silvia Gutierrez for her contributions to preliminary experiments. M. Hennig is grateful for the assistance of Daniel Bearden and Jason Winnike and benefited from helpful discussions through the course of this work.
Grant Support
S.A. Krupenko was supported by the DK54388 grant from the NIH and S.D. Hursting was supported by the CA197627 grant from the NIH.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.